Literature DB >> 15855355

Pharmacodynamic characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a novel, functionally selective nociceptin/orphanin FQ peptide receptor partial agonist with sodium-potassium-sparing aquaretic activity.

Daniel R Kapusta1, Christian Thorkildsen, Velga A Kenigs, Eddi Meier, Mette M Vinge, Charlotte Quist, Jørgen Søberg Petersen.   

Abstract

In conscious rats, intravenous (i.v.) administration of the hexapeptide Ac-RYYRWK-NH(2), a partial agonist of the nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor, produces a selective water diuresis without marked cardiovascular or behavioral effects. The present study examined the in vitro and in vivo pharmacodynamic profile of the novel and potentially metabolically stable NOP receptor ligand ZP120 (Ac-RYYRWKKKKKKK-NH(2)), which was created by conjugation of a structure-inducing probe (SIP) (i.e., K(6) sequence) to Ac-RYYRWK-NH(2). In cells transfected with human NOP receptors, both Ac-RYYRWK-NH(2) and ZP120 displaced [(3)H]N/OFQ (both peptides, pK(i) = 9.6), and similar to N/OFQ inhibited forskolin-induced cAMP formation (Ac-RYYRWK-NH(2), pEC(50) = 9.2; ZP120, 9.3; N/OFQ, 9.7). In the mouse vas deferens assay (MVD), Ac-RYYRWK-NH(2) and ZP120 behaved as partial agonists, inhibiting electrically induced contractions with similar pEC(50) values (9.0 and 8.6, respectively) but with submaximal efficacy compared with N/OFQ. In MVD, both peptides blocked the responses to N/OFQ, with ZP120 being approximately 50-fold more potent than Ac-RYYRWK-NH(2). In vivo, dose-response studies in rats showed that at doses (i.v. bolus or i.v. infusion) that produced a sodium-potassium-sparing aquaresis, ZP120 and Ac-RYYRWK-NH(2) elicited a mild vasodilatory response without reflex tachycardia. However, the renal responses to ZP120 were of greater magnitude and duration. Finally, each peptide blocked the bradycardia and hypotension to N/OFQ in conscious rats, but the effect of ZP120 was of much greater duration. Together, these findings demonstrate that ZP120 is a novel, functionally selective SIP-modified NOP receptor partial agonist with increased biological activity and sodium-potassium-sparing aquaretic activity, the actions of which may be useful in the management of hyponatremia/hypokalemia in water-retaining states.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855355     DOI: 10.1124/jpet.105.083436

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Authors:  Nurulain T Zaveri
Journal:  J Med Chem       Date:  2016-03-14       Impact factor: 7.446

Review 2.  UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.

Authors:  Girolamo Calo'; Anna Rizzi; Carlo Cifani; Maria Vittoria Micioni Di Bonaventura; Domenico Regoli; Maurizio Massi; Severo Salvadori; David G Lambert; Remo Guerrini
Journal:  CNS Neurosci Ther       Date:  2010-05-18       Impact factor: 5.243

3.  Cardiovascular and renal effects of novel nonpeptide nociceptin opioid peptide receptor agonists.

Authors:  Ian B Denys; Juan Gao; Jane C Sutphen; Nurulain T Zaveri; Daniel R Kapusta
Journal:  Br J Pharmacol       Date:  2021-12-12       Impact factor: 8.739

4.  Functional pharmacological characterization of SER100 in cardiovascular health and disease.

Authors:  Inmaculada C Villar; Kristen J Bubb; Amie J Moyes; Eva Steiness; Trygve Gulbrandsen; Finn Olav Levy; Adrian J Hobbs
Journal:  Br J Pharmacol       Date:  2016-11-01       Impact factor: 8.739

5.  Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein G alpha qi5.

Authors:  Valeria Camarda; Carmela Fischetti; Nicholas Anzellotti; Paola Molinari; Caterina Ambrosio; Evi Kostenis; Domenico Regoli; Claudio Trapella; Remo Guerrini; Salvadori Severo; Girolamo Calo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-01-28       Impact factor: 3.000

6.  In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor.

Authors:  Anna Rizzi; Barbara Spagnolo; Richard D Wainford; Carmela Fischetti; Remo Guerrini; Giuliano Marzola; Anna Baldisserotto; Severo Salvadori; Domenico Regoli; Daniel R Kapusta; Girolamo Calo
Journal:  Peptides       Date:  2007-05-06       Impact factor: 3.750

7.  ZP120 causes relaxation by pre-junctional inhibition of noradrenergic neurotransmission in rat mesenteric resistance arteries.

Authors:  U Simonsen; B E Laursen; J S Petersen
Journal:  Br J Pharmacol       Date:  2008-01-14       Impact factor: 8.739

8.  Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic.

Authors:  G Calo; D G Lambert
Journal:  Br J Anaesth       Date:  2018-08-22       Impact factor: 9.166

9.  Discovery of lixisenatide analogues as long-acting hypoglycemic agents using novel peptide half-life extension technology based on mycophenolic acid.

Authors:  Chunli Tang; Qing Li; Xiaoyan Deng; Weiwei Wu; Liufeng Liao; Kai Liang; Rongrui Huo; Chenglin Li; Jing Han; Weizhong Tang; Neng Jiang
Journal:  RSC Adv       Date:  2020-03-25       Impact factor: 3.361

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.